Logo

American Heart Association

  2
  0


Final ID: EPI7

Age-Varying Implications of Recalibration of Cardiovascular Disease Risk Prediction in a New England-Based Healthcare System

Abstract Body (Do not enter title and authors here): Introduction: Atherosclerotic cardiovascular disease (ASCVD) risk estimation via the 2013 Pooled Cohort Equations (PCE) overestimates risk in population-based cohorts. We evaluated its recalibration performance in a contemporary healthcare cohort.

Methods: We identified 160,926 patients in the Mass General Brigham healthcare system aged 40-79 years and without prior ASCVD or lipid-lowering medication use between 2010 and 2012. Recalibration was achieved using sex- and race-specific baseline survival and risk factor distributions of the derivation (80%) set. Internal validation compared Kaplan-Meier-adjusted observed and predicted risk based on original versus recalibrated PCE. Changes in sensitivity and specificity were calculated across various treatment thresholds for each age decile.

Results: Of the 160,926 patients (mean [SD] age: 54.6 [8.6] years; 61.4% female; 82.7% non-Hispanic White), 20,373 (12.7%) underwent ASCVD over 10 years. The original PCE underestimated ASCVD risk (observed vs. predicted incidence rate: 0.13 vs. 0.05) globally and across all sex, race, and risk categories. After recalibration (observed vs. predicted incidence rate: 0.13 vs. 0.18), the prediction closely mirrored the actual ASCVD incidence in low-to-borderline risk but overestimated risk in the high risk. At ≥7.5% treatment threshold, patients aged 40-49 years derived the greatest net relative benefit (sensitivity: +42.9%; specificity: -26.6%) whereas the extent of specificity loss surpassed that of sensitivity gain beyond age 50 years with minimal reclassification by seventh decade in life. Treatment threshold yielding the greatest net benefit was incrementally higher with older age from ≥7.4% in age 40-49 years to ≥24.1% in 60-69 years.

Conclusion: In healthcare setting, PCE significantly underestimated risk. Recalibration recovered sensitivity at the expense of reduced specificity in age-differential manner, highlighting the need for individualized prediction and clinical decision-making.
  • Cho, So Mi  ( Broad Institute of MIT and Harvard , Cambridge , Massachusetts , United States )
  • Natarajan, Pradeep  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Rivera, Rachel  ( Broad Institute of MIT and Harvard , Cambridge , Massachusetts , United States )
  • Koyama, Satoshi  ( Broad Institute of MIT and Harvard , Cambridge , Massachusetts , United States )
  • Kim, Min Seo  ( Broad Institute of MIT and Harvard , Cambridge , Massachusetts , United States )
  • Honigberg, Michael  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Bhattacharya, Romit  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Paruchuri, Kaavya  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Allen, Norrina  ( Northwestern University Feinberg School of Medicine , Chicago , Illinois , United States )
  • Hornsby, Whitney  ( Broad Institute of MIT and Harvard , Cambridge , Massachusetts , United States )
  • Author Disclosures:
    So Mi Cho: DO NOT have relevant financial relationships | Pradeep Natarajan: DO have relevant financial relationships ; Researcher:Allelica:Active (exists now) ; Advisor:Preciseli:Active (exists now) ; Advisor:MyOme:Active (exists now) ; Advisor:Esperion Therapeutics:Active (exists now) ; Advisor:TenSixteen Bio:Active (exists now) ; Consultant:Novartis:Active (exists now) ; Consultant:Genentech / Roche:Active (exists now) ; Consultant:Eli Lilly & Co:Active (exists now) ; Researcher:Novartis:Active (exists now) ; Researcher:Genentech / Roche:Active (exists now) | Rachel Rivera: DO NOT have relevant financial relationships | Satoshi Koyama: DO NOT have relevant financial relationships | Min Seo Kim: DO NOT have relevant financial relationships | Michael Honigberg: DO have relevant financial relationships ; Advisor:Miga Health:Active (exists now) ; Research Funding (PI or named investigator):Novartis:Expected (by end of conference) ; Consultant:Comanche Biopharma:Past (completed) ; Research Funding (PI or named investigator):Genentech:Active (exists now) | Romit Bhattacharya: DO have relevant financial relationships ; Advisor:Casana Care, Inc:Past (completed) ; Advisor:Novartis:Past (completed) | Kaavya Paruchuri: DO NOT have relevant financial relationships | Norrina Allen: DO NOT have relevant financial relationships | Whitney Hornsby: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Best of AHA Specialty Conferences: EPI/Lifestyle 2024

Monday, 11/18/2024 , 10:30AM - 11:30AM

Best of Specialty Conferences

More abstracts from these authors:
Racial Disparities in Low-Density Lipoprotein Cholesterol Control and Lipoprotein(a) Testing Among Young Adult Women with Severe Hyperlipidemia

Jowell Amanda, Cho So Mi, Faaborg-andersen Christian, Yu Zhi, Natarajan Pradeep, Honigberg Michael, Harrington Colleen

Geographic polygenic heterogeneity of obesity across the United States

Truong Buu, Nakao Tetsushi, Koyama Satoshi, Bhattacharya Romit, Honigberg Michael, Hornsby Whitney, Natarajan Pradeep

You have to be authorized to contact abstract author. Please, Login
Not Available